Hartmut Geiger1, Yi Zheng. 1. Department of Dermatology and Allergic Diseases, University of Ulm, Ulm, Germany. hartmut.geiger@uni-ulm.de
Abstract
PURPOSE OF REVIEW: Hematopoietic stem cells (HSCs) continuously provide mature blood cells during the lifespan of a mammal. The functional decline in hematopoiesis in the elderly, which involves a progressive reduction in the immune response and an increased incidence of myeloid malignancy, is partly linked to HSC aging. Molecular mechanisms of HSC aging remain unclear, hindering rational approaches to slow or reverse the decline of HSC function with age. Identifying conditions under which aged HSCs become equivalent to young stem cells might result in treatments for age-associated imbalances in lymphopoiesis and myelopoiesis and in blood regeneration. RECENT FINDINGS: Aging of HSCs has been for a long time thought to be an irreversible process imprinted in stem cells due to the intrinsic nature of HSC aging. Mouse model studies have found that aging is associated with elevated activity of the Rho GTPase Cdc42 in HSCs that is causative for loss of polarity, altered epigenetic modifications and functional deficits of aged HSCs. The work suggests that inhibition of Cdc42 activity in aged HSCs may reverse a number of phenotypes associated with HSC aging. SUMMARY: Maintaining the regenerative capacity of organs or organ systems may be a useful way to ensure healthy aging. A defined set of features phenotypically separate young from aged HSCs. Aging of HSCs has been thought to be irreversible. Recent findings support the hypothesis that functional decline of aged HSCs may be reversible by pharmacological intervention of age altered signaling pathways and epigenetic modifications.
PURPOSE OF REVIEW: Hematopoietic stem cells (HSCs) continuously provide mature blood cells during the lifespan of a mammal. The functional decline in hematopoiesis in the elderly, which involves a progressive reduction in the immune response and an increased incidence of myeloid malignancy, is partly linked to HSC aging. Molecular mechanisms of HSC aging remain unclear, hindering rational approaches to slow or reverse the decline of HSC function with age. Identifying conditions under which aged HSCs become equivalent to young stem cells might result in treatments for age-associated imbalances in lymphopoiesis and myelopoiesis and in blood regeneration. RECENT FINDINGS: Aging of HSCs has been for a long time thought to be an irreversible process imprinted in stem cells due to the intrinsic nature of HSC aging. Mouse model studies have found that aging is associated with elevated activity of the Rho GTPase Cdc42 in HSCs that is causative for loss of polarity, altered epigenetic modifications and functional deficits of aged HSCs. The work suggests that inhibition of Cdc42 activity in aged HSCs may reverse a number of phenotypes associated with HSC aging. SUMMARY: Maintaining the regenerative capacity of organs or organ systems may be a useful way to ensure healthy aging. A defined set of features phenotypically separate young from aged HSCs. Aging of HSCs has been thought to be irreversible. Recent findings support the hypothesis that functional decline of aged HSCs may be reversible by pharmacological intervention of age altered signaling pathways and epigenetic modifications.
Authors: Derrick J Rossi; David Bryder; Jun Seita; Andre Nussenzweig; Jan Hoeijmakers; Irving L Weissman Journal: Nature Date: 2007-06-07 Impact factor: 49.962
Authors: Melissa Dumble; Lynette Moore; Stuart M Chambers; Hartmut Geiger; Gary Van Zant; Margaret A Goodell; Lawrence A Donehower Journal: Blood Date: 2006-10-10 Impact factor: 22.113
Authors: Zhenyu Ju; Hong Jiang; Maike Jaworski; Chozhavendan Rathinam; Anne Gompf; Christoph Klein; Andreas Trumpp; K Lenhard Rudolph Journal: Nat Med Date: 2007-05-07 Impact factor: 53.440
Authors: Hongjun Liu; Maria M Fergusson; Rogerio M Castilho; Jie Liu; Liu Cao; Jichun Chen; Daniela Malide; Ilsa I Rovira; Daniel Schimel; Calvin J Kuo; J Silvio Gutkind; Paul M Hwang; Toren Finkel Journal: Science Date: 2007-08-10 Impact factor: 47.728
Authors: Andrew S Brack; Michael J Conboy; Sudeep Roy; Mark Lee; Calvin J Kuo; Charles Keller; Thomas A Rando Journal: Science Date: 2007-08-10 Impact factor: 47.728
Authors: Stuart M Chambers; Chad A Shaw; Catherine Gatza; C Joseph Fisk; Lawrence A Donehower; Margaret A Goodell Journal: PLoS Biol Date: 2007-08 Impact factor: 8.029
Authors: Anastasia Nijnik; Lisa Woodbine; Caterina Marchetti; Sara Dawson; Teresa Lambe; Cong Liu; Neil P Rodrigues; Tanya L Crockford; Erik Cabuy; Alessandro Vindigni; Tariq Enver; John I Bell; Predrag Slijepcevic; Christopher C Goodnow; Penelope A Jeggo; Richard J Cornall Journal: Nature Date: 2007-06-07 Impact factor: 49.962
Authors: Maria Almeida; Ha-Neui Kim; Li Han; Daohong Zhou; Jeff Thostenson; Ryan M Porter; Elena Ambrogini; Stavros C Manolagas; Robert L Jilka Journal: Aging Cell Date: 2020-10-13 Impact factor: 9.304